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Abstract
Objectives—To better understand the effectiveness of xylitol in caries prevention in adults, and
to attempt improved clinical trial efficiency.
Methods—As part of the Xylitol for Adult Caries Trial (X-ACT), non-cavitated and cavitated
caries lesions were assessed in subjects who were experiencing the disease. The trial was a test of
the effectiveness of 5 grams/day of xylitol, consumed by dissolving in the mouth five 1 gram
lozenges spaced across each day, compared with a sucralose placebo. For this analysis, seeking
trial efficiency, 538 subjects aged 21–80, with complete data for four dental examinations were
selected from the 691 randomized into the three year trial, conducted at three sites. Acceptable
inter and intra examiner reliability before and during the trial was quantified using the kappa
statistic.
Results—The mean annualized non-cavitated plus cavitated lesion transition scores in coronal
and root surfaces, from sound to carious favoured xylitol over placebo, during the three
cumulative periods of 12, 24, and 33 months, but these clinically and statistically non-significant
differences declined in magnitude over time. Restricting the present assessment to those subjects
with a higher baseline lifetime caries experience showed possible but inconsistent benefit.
Conclusions—There was no clear and clinically relevant preventive effect of xylitol on caries in
adults with adequate fluoride exposure when non-cavitated plus cavitated lesions were assessed.
This conformed to the X-ACT trial result assessing cavitated lesions. Including non-cavitated
lesion assessment in this full scale, placebo controlled, multi site, randomized, double blinded
clinical trial in adults experiencing dental caries, did not achieve added trial efficiency or
demonstrate practical benefit of xylitol.
Trial Registration—ClinicalTrials.Gov NCT00393055
John P Brown, BDS MS PhD, University of Texas Health Science Center at San Antonio, Department of Comprehensive Dentistry,
7703 Floyd Curl Drive, MC 7914, San Antonio, TX 78229-3900 USA, 210-567-3450, Fax 210-567-3443, brown@uthscsa.edu.
NIH Public Access
Author Manuscript
Community Dent Oral Epidemiol. Author manuscript; available in PMC 2015 June 01.
Published in final edited form as:























Xylitol; Dental Caries Prevention; Randomized Controlled Trial; Adults; Early Caries Lesion;
Clinical Trial Efficiency; non-cavitated caries lesion
Introduction
A consensus conference (1) has called for methods for shorter and less costly clinical trials
so that more caries preventive agents may be tested for efficacy and effectiveness. With a
better evidence base, new preventive agents may be more confidently advocated and more
widely used in public health programs and by individuals. In vitro and in vivo equivalence
tests, which do not provide direct evidence of clinical efficacy, have taken precedence for
established preventive agents and are not applicable for new agents. Shorter trials are likely
to be more feasible when using participants with higher caries activity and incidence, but
then the results will be less generalizable to the whole population. One way to make these
trials more cost effective may be to employ different methods than visual cavitated caries
lesion assessment (2, 3, 4). Another strategy may be to use visual assessments at earlier
stages of the caries lesion’s progressive but initially reversible continuum (1, 5, 6, 7).
An important aspect of efficacy in caries prevention involves not only the agent’s ability to
inhibit the progress to cavitation (D2), but also in promoting the prevention, arrest or
reversal of visible but non-cavitated (D1) lesions. Such effects also occur at even earlier
mineral dissolution stages that are not visible. All of these possibilities could result in fewer
lesions at all stages. Traditional cavitated lesion assessment takes no specific account of
such multifaceted arrest and remineralisation. Yet these are features of the disease with
potential to be harnessed for prevention. Xylitol may have such preventive attributes
involving remineralisation (8). There are several proposed indirect mechanisms through
which xylitol could be associated with enhanced remineralisation and decreased
demineralisation (9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23). Recent
metabolomic analysis in vivo suggests that xylitol is not an inhibitor of plaque metabolism
in acid production, but acts as a non-fermentative sugar alcohol (24). Thus some proposed
mechanisms may have to be reconsidered.
The Xylitol for Adult Caries Trial (X-ACT) tested the hypothesis that daily use of xylitol
lozenges (5 grams/day) will reduce dental caries incidence in caries-active adults. Evidence
for xylitol efficacy from systematic reviews is controversial and unresolved (23, 25, 26, 27,
28, 29, 30, 31, 32). The effectiveness at the level of combined cavitated coronal and root
lesions (D2) and safety outcomes from this trial have been published (33). Subjects showed
no consistent, significant or clinically meaningful benefit from xylitol, for coronal and root
lesions combined, when this was assessed at the cavitated lesion threshold. Xylitol was
however shown to prevent D2 level root caries in this trial (48). Relatively few root lesions
developed in these subjects and this effect was only apparent in this tooth surface specific
analysis. The X-ACT trial also included caries assessments at the non-cavitated level for
crown and root lesions (D1) as part of an explicit aim to determine if the use of such
assessments might have led to earlier results than the D2 based analysis. Criteria were
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derived from the International Caries Detection and Assessment System (34, 35). No
attempt was made to distinguish between active and inactive lesions as additionally
prescribed by ICDAS.
The reliability of ICDAS and related assessment methods has not been fully established for
application in clinical trials, within and between multiple clinical examiners at several sites
and over several years. There have been other validation and reliability tests of the ICDAS
and Nyvad proposed systems of caries lesion assessment, which include early lesions (3, 36,
37, 38). A one year test of ICDAS criteria, though in differing groups of children and with
very close repeat examinations, showed good to excellent inter- and intra-examiner
reliability for lesion severity (39). These reliability tests do not fully exemplify and satisfy
the multiexaminer, multisite and duration demands of full scale clinical trial calibrations
(35). Two clinical trials have been completed using ICDAS based criteria. One unreported
study assessed only two teeth per subject, not caries of each tooth surface in the whole
dentition (40). Another with three clinical assessments showed no efficiency benefit over 13
months, by including non-cavitated lesions (41).
Thus the aims of this paper are:
1. To determine if a result of the trial using D1 plus D2 lesion data could have been
obtained in the first or second year of the three year trial;
2. To contrast these results to that obtained at the more advanced and traditional caries
lesion stage (D2) after one, two, and three years; and
3. To determine if trial subjects with higher initial caries scores, and presumed to have
higher caries activity, showed a greater caries preventive effect of xylitol using D1
plus D2 lesion level data over one, two, and three years.
Materials and Methods
The design and methods of the X-ACT trial have been published (42) including subject
recruitment, caries scoring matrices, safety monitoring, power and samples size estimates
and analytic methods. The caries criteria, examiner training methods and reliability
assessments have also been described and assessed (35), including those involving both D1
and D2 level lesions, and are not repeated here.
There were three clinical study sites for X-ACT at the University of North Carolina-Chapel
Hill (UNC), the University of Alabama-Birmingham (UAB), and the University of Texas
Health Science Center – San Antonio (UTHSC-SA). The Kaiser Permanente Center for
Health Research-Portland Oregon (KPCHR) served as the Data Coordinating Center. The
study was approved by the Institutional Review Board at each of the four participating
institutions and all participants provided informed consent in writing.
Inclusion criteria were age 21–80 years, the presence of at least one coronal or root surface
cavitated caries lesion (present at screening, or documented in the patient record or by self-
report as having been restored in the previous year), presence of at least 12 teeth, ability to
read and understand English, and ability to give informed consent. Exclusion criteria were
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the presence of extensive caries (more than 10 teeth with lesions), periodontal disease
requiring aggressive treatment, residing in same household with another participant, or
anticipated moving within three years. A total of 691 individuals met these criteria and were
randomized into the study. From these we excluded 10 subjects randomized in error (part of
dual households), an additional 5 subjects with missing data for other variables used in the
analyses and for this report 138 subjects who failed to attend all the dental examinations.
This left a total of 538 subjects with complete data (78% of the original subjects) for this
analysis.
To select all subjects could have caused the result to reflect any possible systematic trends in
non-participation in these timed examinations. By selecting full participants only, the results
relate to time frame, not dropout effects plus time frame. This also avoided complexities in
imputing missing data over three time periods, versus one period of 33 months as was done
for the D2 level outcome analysis. There was moreover, no “intent to treat” for the purpose
of this particular analysis, so it seemed reasonable to select only those subjects with
complete data at all four time points.
Subjects were asked to dissolve five lozenges in the mouth daily, each containing 1 gram of
xylitol or a placebo of identical size, shape, color and flavor (peppermint), containing
sucralose which, unlike xylitol, lacks clinically demonstrated cariostatic or cariogenic
properties. These were not commercial products, but formulated for the trial. Sucralose, but
not xylitol, has been shown in vitro to affect glucosyltransferases (43), but has no known
effect on caries itself in animal models or in humans. Both test and placebo could equally
have replaced some sugars in the diet, and caused some salivary stimulation, which might
relate to caries increment.
Trained and calibrated examiners visually identified caries lesions by using a CPITN-E
probe, a non-magnifying plane mirror, and standard dental operating light and chair. Loupes
were used at the discretion of the examiner, but consistently within each examiner. Tooth
surfaces were dried for five seconds with an air/water syringe. Examiners used a
modification of the International Caries Detection and Assessment System criteria (34), with
two disease levels possible for each coronal surface; sound (S), non-cavitated enamel lesion
(D1) (ICDAS codes 1 & 2): cavitated lesion penetrating the enamel (ICDAS code 3) plus
cavitated lesions penetrating into dentin or “shadowing” (ICDAS codes 4, 5 and 6),
combined in this report as D2. Root surfaces were scored as sound (S), lesion with estimated
depth <0.5mm (D1), and lesion with estimated depth ≥0.5mm (D2). Other surface conditions
noted were pit and fissure sealants (P), restorations (F), crowns (C), missing teeth (M), and
surfaces unable to be scored (Y). Examiners made one classification per tooth surface, and
each tooth was deemed to have five coronal (including the incisal) surfaces and up to four
root surfaces if exposed.
A primary examiner at each clinical center completed almost all examinations with a
recorder; 100% at UAB, 98% at UNC, and 96% at UTHSC-SA, although back-up examiners
were available as needed. To the extent possible, all follow-up examinations were performed
by the same examiner who conducted the baseline examination. Primary and back-up
examiners and recorders from all three clinical centers participated in a four-day training and
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calibration session with a benchmark examiner (35), as well as refresher sessions prior to the
12-, 24-, and 33-month examinations, the study being shortened by three months in the third
year. All primary examiners completed second examinations of approximately 5% of
participants annually to determine intra-examiner reliability.
For this analysis the impact of the xylitol lozenges on two separate outcomes was compared;
the cumulative cavitated and non-cavitated Decayed or Filled Surface (D12FS) increment
and the cumulative cavitated Decayed or Filled Surface (D2FS) increment. The cumulation
periods were 0–12 months, and 0–12+12–24 months and 0–12 +12–24 + 24–33 months,
increments then being annualised for comparability. The transition weighting matrices for
each score are described and justified elsewhere, (42) and both increment scores were for
root and coronal surfaces combined.
Several measures were created to characterize participants at baseline and their oral health
and oral healthcare practices. These included race/ethnicity, age, gender, a binary indicator
of a routine dental visit (exam or cleaning) in the past year; a two-level indicator of fluoride
use (in toothpaste or professional topical fluoride, or both), two indicators of oral hygiene
practices (brushing and flossing) and self-reported dry mouth. All three clinical study sites
are served by community water fluoridation. Forms used for all data collection are available
on the study’s public website, http://www.xactstudy.org
For purposes of analysis, the increment data was Winsorised constraining outlying values to
be no smaller than the 1st or larger than the 99th percentiles. Because the D12FS lesion
transition scores were normally distributed, they were analyzed using linear regression
analysis. D2FS increments were non-negative, positively skewed, and overdispersed; thus,
negative binomial regression was used, which yields coefficients that have the interpretation
of ln (rate ratios) as opposed to absolute differences in increment from the D12FS models.
For purposes of presentation, these coefficients were exponentiated to yield rate ratios. In
addition to the different interpretation of co-efficients from the two models, absolute
differences in the two outcomes cannot be directly compared because different transition
weighting matrices were used for them, which are fully explained in an associated paper
(42). Nevertheless, the outcomes from these two regression models may still be contrasted,
including as a test for increased trial efficiency by including non-cavitated lesions.
For each outcome measure and each interval of time, regression models were fitted that
included a binary indicator of treatment status and clinical center, age, age-squared, dental
cleaning history, self-fluoride use, and oral hygiene practices. Because this analysis was
limited to only those individuals attending all measurement visits, all analyses were based
on the same set of subjects and hence any differences in results between models cannot be
attributed to differences in subjects. A parallel series of analyses were also conducted for the
subset of 216 subjects whose baseline D2FS score was 21 or higher and were thus presumed
to be at higher risk of caries (44).
All analyses were conducted using SAS version 9.2 and a p-valued of 0.05 was deemed to
be statistically significant.
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For the primary examiners, intra-examiner reliability scores are reported based on a roughly
5% convenience sample of all participants, not just those selected for this paper, who
returned for repeat examinations during the study. To assess reliability, weighted kappa
statistics were computed for distinguishing S versus D1 versus D2 lesions. Representative
kappa values are reported.
Results
The base line characteristics of the 266 xylitol and 272 placebo group subjects were similar
to each other (Table 1) and to those in the full randomised sample [data not shown, (33)].
Adherence, assessed by quarterly self report, was a mean of 3.8 lozenges (range 4.3–3.3) of
the target of 5 lozenges consumed the day prior, and a mean of 4.3 days (range 5.2–3.6) of
the 7 prior days in which a minimum 5 or more lozenges were consumed. Adherence
assessed quarterly at resupply, as cumulative lozenges dispensed as a percentage of number
expected was a mean of 73.3% (range 84.2–58.3%), declining over time. These subjects had
a high degree of self-reported topical fluoride exposure (≥90%), and all three sites had
community water fluoridation. The intra-examiner reliability weighted kappa scores for all
primary examiners for reliability in distinguishing S versus D1 versus D2 were as follows:
baseline 0.63, 12 months 0.84, 24 months 0.66, 33 months 0.67.
The mean annual non-cavitated and cavitated lesion transition scores (D12FS) for Xylitol
and Placebo groups were contrasted with the cavitated lesion transition scores (D2FS) for all
subjects selected for this analysis, over three cumulative periods, and then annualised, Table
2. This shows mean annual difference in transition scores for D12FS favouring xylitol, but
declining in magnitude over these time periods from −1.23 to −0.54 to −0.17. None of these
differences were statistically significant. The comparable cavitated lesion (D2FS) transition
rate ratios (natural log scale) also favoured xylitol over placebo. The differences in these
mean transition scores also declined over time. These rate ratio were statistically significant
only in year one.
Thus, for Aim 2, the inclusion of non-cavitated and cavitated caries lesions failed to reveal a
substantative and consistent effect of xylitol over placebo over three time periods; neither
had the traditional cavitated lesion assessment over the full 33 months of the trial (33).
Furthermore, for Aim 1, the inclusion of non-cavitated lesions did not allow this trial to
reach a definitive result in a shorter time.
The result of the X-ACT trial at the cavitated lesion level (33) showed xylitol had an eleven
percent but non-statistically significant caries reduction over a placebo lozenge. But when
participants with higher baseline caries scores, and presumably greater caries activity, were
selected for a comparable analysis, the preventive effect of xylitol at the D2 level was found
to be statistically significant over 33 months for annualised scores (33). Therefore, in
parallel with this, we also studied a subsample of subjects with more severe baseline caries
(D2FS>20), Table 3 (n=216, xylitol group n=111 and Placebo group n=105).
This analysis of subjects with higher lifetime caries experience (Table 3) showed a mean
annual difference in transition scores for D12FS favouring xylitol, and declining over 12, 24
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and 33 months from −2.93 (p =.005) to −1.15 (p =.10) to −0.66 (p=.05). This contrasts with
the analysis in these subjects for D2FS transition scores which favoured xylitol, and declined
over 12, 24 and 33 months, with the rate ratios statistically significant over 12 and 24
months only.
Therefore, under Aim 3, this analysis determined that trial subjects with greater lifetime
caries experience showed an inconsistent and equivocal benefit from xylitol.
Discussion
This methodologically oriented analysis found no design efficiency by including non-
cavitated lesions, either in preventive effect or time to detection. The X-ACT trial evaluated
lozenges not gum as the vehicle to rule out the complex covariate effects of substantial
masticatory salivary stimulation (45, 46) and possible plaque removal by mastication, that
may plausibly help explain any positive effects. The trial studied effects in adults, not
children or adolescents, and they were exposed to adequate fluoride. No dose response effect
was reported (33). While the threshold daily dose and frequency of consumption of xylitol
are not definitively determined, the most adherent subjects in this trial were consuming 5
grams/day, which is the most recent suggested threshold dose (47), so an effect could be
expected to be detectable under the conditions of this trial. Furthermore, the subjects were
experiencing caries throughout the trial. The measured risk reduction was of the same order
at all three clinical sites. The result does not appear to have occurred due to inadequate
intake or inability to detect an effect of xylitol, due to our methods. Xylitol caries risk
reduction appears to be quite low in adults experiencing the disease, who also have adequate
fluoride exposure.
It is possible that D1 lesions were being retarded by xylitol earlier than at 12 months, and
this was not directly detected in this trial. If xylitol had been acting to prevent lesion
progress from sound to non-cavitated (D1) or to prevent these from progressing to cavitated
lesions (D2), then assessing D1 and D2 lesions could be expected to show a difference over
D2 lesions alone. This was not revealed. If retardation of progress of enamel caries was
occurring, then detection of this effect might have been found whether assessing D12 or D2
lesions, and sooner, after 12 or 24 months rather than 33 months. A lesion retardation effect
of xylitol was not observed in this study.
The observed preventive effect of xylitol diminished over cumulative time periods in this
analysis for both cavitated and non-cavitated plus cavitated lesions. While absolute changes
in the subjects as a whole may be influenced by regression to the mean or Hawthorne
effects, treatment comparisons should be unaffected with randomization, and this bias
should not affect the comparisons that are the focus of this paper. The xylitol effect was
small and declined over time. It also lacked consistent statistical significance over time. If
this were due to a short-term xylitol effect, then it could be expected to be more clearly
evident while including non-cavitated lesions in the assessment. This was not the case. The
preventive effect was nominally greater when non-cavitated lesions were included, but then
the total number of lesions being assessed was greater. It has been suggested that Xylitol
acts to reverse, prevent or inhibit progression of early caries. If the intervention was more
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(or less) successful by including D1 lesions in the assessment, a change in the effect size
over assessment of D2 lesions alone would be expected, but this was not found. Overall the
lack of consistency in statistical significance at all time periods, the declining effect over
time, and the small degree of effect are not commensurate with an interpretation of a
clinically relevant preventive effect of xylitol. Any possible advantage conferred from
detecting more events appears to be more than offset by added variability, as evidenced by
the ever-widening confidence intervals in going from the 3-year annualized increment to the
1-year annualised increment. By contrast the CIs for the cavitated lesion analysis are fairly
stable (Table 2).
Prior attempts to investigate the potential for shortening caries clinical trials by inclusion of
visual and other assessments of non-cavitated lesions are not fully convincing. A successful
reliability and validity study (36) involving two groups of ten examiners, involved
calibration only once prior to the study proper. A comparison of the diagnostic yield of
several types of visual and other examinations at the non-cavitated lesion threshold,
including tooth separation, fiber optic transillumination and electronic caries measurement
(in some subjects only) was made (3). The 182 Latvian children had a high caries
experience, and the reliability measurements were made once only. These authors concluded
that use of these alternative caries detection methods was feasible.
Alternative methods to visual caries detection hold promise of increased efficiency, but
validation of these methods in detecting earlier stage lesions in full scale trials remains
problematic, and additionally they must be related to the efficacy of established preventive
agents assessed at the cavitated stage (6, 7). When validity is assured, examiner reliability in
use of these newer detection methods will then have to be fully demonstrated under trial
conditions. This dual requirement remains a very big challenge to improved trial efficiency.
In this study acceptable examiner reliability in visually assessing caries at the non-cavitated
and cavitated lesions stages was attained and maintained under full clinical trial conditions.
The additional effort to include non-cavitated lesions was considerable.
Assessments of non-cavitated caries lesions did not add to an understanding of the stage of
lesion formation potentially affected by xylitol, and did not indicate that any shortening of
this trial might have thereby been possible. This conclusion applied also to selected subjects
of higher lifetime caries experience. Xylitol benefit was not shown. Enthusiasm for xylitol
as a caries preventive agent in programs or for individuals should be tempered by these
clinical trial findings in caries active adults with adequate fluoride exposure.
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Table 1
Sample characteristics by demography and oral health behaviours
All sites Treatment n=266 Control n=272 Total n=538
Race/Ethnicity
 Non-Hispanic white 48.9% 52.6% 50.7%
 Non-Hispanic black 27.1% 25.0% 26.0%
 Hispanic 19.9% 19.5% 19.7%
 Other 3.8% 2.9% 3.4%
Age 47.3 (13.4)1 48.8 (13.5)1 48.1 (13.4)1
Female 60.2% 67.3% 63.8%
Brushes 2+ times/day 63.2% 70.6% 66.9%
Flosses 1+ times/day 48.9% 47.8% 48.3%
Routine (exam/clean) dental visit in past year 34.2% 28.3% 31.2%
Self-report dry mouth 5.6% 9.6% 7.6%
Extent of fluoride exposure (2 mutually exclusive categories)
 Toothpaste or prof. topical fluoride 52.3% 62.9% 57.6%
 Both toothpaste and prof. topical fluoride 37.6% 29.8% 33.6%
 Any above topical fluoride exposure (sum) 89.9% 92.7% 91.2%
1
data expressed as mean (Standard deviation)
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